Rigel制药 RIGL 深 沪
已收盘 08-15 16:00:00 美东时间
39.51
+1.620
+4.28%
华盛通- 最 高39.68
- 今 开38.30
- 成交量 76.17万股
- 最 低 37.5001
- 昨 收 37.89
- 总市值 7.06亿
- 52周最高 39.68
- 市盈率 静 39.97
- 换手率 4.26%
- 52周最低 12.04
- 委 比 -95.12%
- 总股本 1787.24万
- 历史最高 114.40
- 量 比 0.68
- 振 幅 5.75%
- 历史最低 6.40
- 每 手 1
- 风险率 2.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
Rigel Pharmaceuticals shares are trading higher after the company reported bett...
08-06 20:31
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceutical...
07-07 20:05
Rigel Pharmaceuticals Approves Equity Plan Amendment
Rigel ( ($RIGL) ) has issued an announcement. On May 22, 2025, Rigel Pharmaceut...
05-24 04:49
Rigel Pharmaceuticals To Present Final GAVRETO Phase 1/2 ARROW Study Data In RET Fusion-Positive NSCLC And Solid Tumors, Along With Supportive REZLIDHIA Data For mIDH1 R/R AML At ASCO And EHA 2025 Conferences
Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with
05-23 05:36
Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results.
Rigel Pharmaceuticals shares are trading higher after the company reported bett...
05-07 04:56
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceutica...
04-04 20:05
Rigel settles patent litigation regarding its immune thrombocytopenia treatment
Rigel Pharmaceuticals (RIGL) announced a settlement agreement with Annora Pharma Private, Hetero Labs, and Hetero USA, resolving an ongoing patent dispute related to TAVALISSE, the company's treatment...
03-27 21:59
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Priv...
03-27 20:05
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors....
03-10 20:05
